{"transactions":[{"id":680556,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:25:46.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":86.96,"value":173920.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":31600,"source":{"system":"sec-edgar","filing":"0001242615-26-000002","document":"wk-form4_1787261143.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000124261526000002/wk-form4_1787261143.xml","form_type":"4"}},{"id":778891,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-05-14T21:47:50.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":22700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders."}],"balance_after":22700,"derivative":{"exercise_price":13.28,"exercise_date":"2027-05-12","expiration_date":"2036-05-12","underlying":"Common Stock","underlying_shares":22700},"source":{"system":"sec-edgar","filing":"0001999371-26-010753","document":"olukotun-form4_051426.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126010753/olukotun-form4_051426.xml","form_type":"4"}},{"id":960276,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:25.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":827,"price":68.48,"value":56632.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.38 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":33600,"source":{"system":"sec-edgar","filing":"0001242615-25-000006","document":"wk-form4_1766530882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000124261525000006/wk-form4_1766530882.xml","form_type":"4"}},{"id":960275,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:25.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":6083,"price":68.04,"value":413887.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.62 to $68.30, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":34427,"source":{"system":"sec-edgar","filing":"0001242615-25-000006","document":"wk-form4_1766530882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000124261525000006/wk-form4_1766530882.xml","form_type":"4"}},{"id":960274,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:25.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":3090,"price":66.7,"value":206103.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.40, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":40510,"source":{"system":"sec-edgar","filing":"0001242615-25-000006","document":"wk-form4_1766530882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000124261525000006/wk-form4_1766530882.xml","form_type":"4"}},{"id":963707,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T23:39:49.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":7819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date."}],"balance_after":43600,"source":{"system":"sec-edgar","filing":"0001242615-25-000004","document":"wk-form4_1766101187.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000124261525000004/wk-form4_1766101187.xml","form_type":"4"}},{"id":1147248,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-05-15T20:49:44.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders."}],"balance_after":10000,"derivative":{"exercise_price":20.18,"exercise_date":"2026-05-13","expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001999371-25-006242","document":"olukotun-form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125006242/olukotun-form4.xml","form_type":"4"}},{"id":1238300,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2025-02-28T22:31:25.000Z","date":"2024-06-10","kind":"other","planned":false,"acquired":false,"shares":0.812,"price":1.91,"value":1.55092,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Involuntary sale of fractional shares following a reverse stock split of the Issuer's common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001839882-25-012471","document":"olukotun-form4_022825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000183988225012471/olukotun-form4_022825.xml","form_type":"4"}},{"id":1294880,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-28T00:22:57.000Z","date":"2025-01-23","kind":"sale","planned":true,"acquired":false,"shares":959,"price":21,"value":20139.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":35781,"source":{"system":"sec-edgar","filing":"0001628280-25-002716","document":"wk-form4_1738023770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025002716/wk-form4_1738023770.xml","form_type":"4"}},{"id":1320686,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-30T22:12:21.000Z","date":"2024-12-27","kind":"sale","planned":true,"acquired":false,"shares":2850,"price":20,"value":57000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":36740,"source":{"system":"sec-edgar","filing":"0001628280-24-052592","document":"wk-form4_1735596735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024052592/wk-form4_1735596735.xml","form_type":"4"}},{"id":1324791,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-20T23:05:14.000Z","date":"2024-12-18","kind":"grant","planned":false,"acquired":true,"shares":16733,"price":22.99,"value":384691.67,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary date."}],"balance_after":39590,"source":{"system":"sec-edgar","filing":"0001628280-24-052273","document":"wk-form4_1734735909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024052273/wk-form4_1734735909.xml","form_type":"4"}},{"id":1501832,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-05-24T21:07:07.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":104621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2025 Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2025 Annual Meeting of Stockholders."}],"balance_after":104621,"derivative":{"exercise_price":0.1745,"exercise_date":"2025-05-23","expiration_date":"2034-05-23","underlying":"Common Stock","underlying_shares":104621},"source":{"system":"sec-edgar","filing":"0001999371-24-006622","document":"olukotun-form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124006622/olukotun-form4.xml","form_type":"4"}},{"id":1705874,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-19T20:54:07.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":14987,"price":25.41,"value":380819.67,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary of the grant date."}],"balance_after":22854,"source":{"system":"sec-edgar","filing":"0001628280-23-041966","document":"wk-form4_1703019238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023041966/wk-form4_1703019238.xml","form_type":"4"}},{"id":1898033,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-05-10T21:11:55.000Z","date":"2023-05-08","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Does not reflect a 1-for-6.25 reverse stock split of the Issuer's common stock effective May 10, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2024 Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2024 Annual Meeting of Stockholders."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Does not reflect a 1-for-6.25 reverse stock split of the Issuer's common stock effective May 10, 2023."}],"balance_after":60000,"derivative":{"exercise_price":0.509,"exercise_date":"2024-05-08","expiration_date":"2033-05-08","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001839882-23-012502","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000183988223012502/ownership.xml","form_type":"4"}},{"id":1970244,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-06T23:04:30.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":11350,"price":32.65,"value":370577.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.36 to $32.88, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":7867,"source":{"system":"sec-edgar","filing":"0001209191-23-016446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919123016446/doc4.xml","form_type":"4"}},{"id":2056905,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-12T01:17:53.000Z","date":"2023-01-10","kind":"grant","acquired":true,"shares":4593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents options, which will vest in one installment on the first anniversary of the grant date."}],"balance_after":4593,"derivative":{"exercise_price":33.03,"exercise_date":"2024-01-10","expiration_date":"2033-01-10","underlying":"Common Stock","underlying_shares":4593},"source":{"system":"sec-edgar","filing":"0001209191-23-003071","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919123003071/doc4.xml","form_type":"4"}},{"id":2056904,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-12T01:17:53.000Z","date":"2023-01-10","kind":"grant","acquired":true,"shares":7867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date."}],"balance_after":19217,"source":{"system":"sec-edgar","filing":"0001209191-23-003071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919123003071/doc4.xml","form_type":"4"}},{"id":2274655,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-05-11T21:40:27.000Z","date":"2022-05-09","kind":"grant","acquired":true,"shares":2131500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan."}],"balance_after":2131500,"derivative":{"exercise_price":0.132,"exercise_date":"2023-05-09","expiration_date":"2032-05-09","underlying":"Common Stock","underlying_shares":2131500},"source":{"system":"sec-edgar","filing":"0001387131-22-006015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713122006015/ownership.xml","form_type":"4"}},{"id":2440703,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-08T01:11:20.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":6400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date."}],"balance_after":11350,"source":{"system":"sec-edgar","filing":"0001209191-22-002593","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122002593/doc4.xml","form_type":"4"}},{"id":2451953,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-05T02:33:55.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":244,"price":66.25,"value":16165.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant\nto a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."}],"balance_after":4950,"source":{"system":"sec-edgar","filing":"0001209191-22-001328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122001328/doc4.xml","form_type":"4"}},{"id":2451952,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-05T02:33:55.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":1916,"price":65.04,"value":124616.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant\nto a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.74 to\n$65.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead\nPharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares\nsold at each separate price within the ranges set forth in this footnote of this Form 4"}],"balance_after":5194,"source":{"system":"sec-edgar","filing":"0001209191-22-001328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122001328/doc4.xml","form_type":"4"}},{"id":2451951,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-05T02:33:55.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":1890,"price":64.26,"value":121451.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant\nto a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.72 to\n$64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead\nPharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares\nsold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":7110,"source":{"system":"sec-edgar","filing":"0001209191-22-001328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122001328/doc4.xml","form_type":"4"}},{"id":2571435,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-14T21:25:27.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":2750,"price":63.76,"value":175340.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":9000,"source":{"system":"sec-edgar","filing":"0001209191-21-055966","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121055966/doc4.xml","form_type":"4"}},{"id":2571434,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-14T21:25:27.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":2250,"price":63.76,"value":143460.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":11750,"source":{"system":"sec-edgar","filing":"0001209191-21-055966","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121055966/doc4.xml","form_type":"4"}},{"id":2716249,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-05-12T20:44:37.000Z","date":"2021-05-10","kind":"grant","acquired":true,"shares":270882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan."}],"balance_after":270882,"derivative":{"exercise_price":1.03,"exercise_date":"2022-05-10","expiration_date":"2031-05-10","underlying":"Common Stock","underlying_shares":270882},"source":{"system":"sec-edgar","filing":"0001387131-21-005546","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713121005546/ownership.xml","form_type":"4"}},{"id":2923325,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-05T23:16:32.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date."}],"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001209191-21-001548","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121001548/doc4.xml","form_type":"4"}},{"id":3055826,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2020-08-17T13:04:43.000Z","date":"2020-08-13","kind":"purchase","acquired":true,"shares":5350,"price":0.94,"value":5029.0,"ownership":{"direct":true},"balance_after":5350,"source":{"system":"sec-edgar","filing":"0001387131-20-007593","document":"olukotun-form4_081320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713120007593/olukotun-form4_081320.xml","form_type":"4"}},{"id":3159350,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-05-06T22:30:36.000Z","date":"2020-05-04","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan."}],"balance_after":75000,"derivative":{"exercise_price":0.77,"exercise_date":"2021-05-04","expiration_date":"2030-05-04","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001387131-20-004489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713120004489/ownership.xml","form_type":"4"}},{"id":3535055,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2019-05-08T11:21:36.000Z","date":"2019-05-06","kind":"grant","acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan."}],"balance_after":30000,"derivative":{"exercise_price":2.05,"exercise_date":"2020-05-06","expiration_date":"2029-05-06","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001387131-19-003412","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713119003412/ownership.xml","form_type":"4"}},{"id":3821941,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2018-09-07T20:08:19.000Z","date":"2018-09-05","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on September 5, 2018 pursuant to the Issuer's 2018 Equity Incentive Plan and vests on the date of the Issuer's 2019 annual meeting of shareholders."}],"balance_after":15000,"derivative":{"exercise_price":1.03,"expiration_date":"2028-09-05","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001615774-18-009357","document":"s112616_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000161577418009357/s112616_form4.xml","form_type":"4"}}]}